IAH is required to purchase minimum quantities of TPM® annually to maintain exclusivity. The minimums in the first year of the launch total approximately $550,000 in revenue to Phosphagenics and they climb to around $1.8 million for the final year of the exclusivity arrangement. In addition to these minimum purchases, IAH is required to pay Phosphagenics royalties on sales to its distributor.
TP...this is for the UK...we've since rolled out to NZ...and if the Americas come on board soon, as expected..we're rock'n.
And lets not forget Europe
..agreed, I was a tad optimistic...the meds had just kicked in..
Ann: Phosphagenics - February 2016 Newsletter, page-36
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(20.0%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $2 | 1.126K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 34751789 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 40153304 | 27 |
View Market Depth
| Last trade - 12.40pm 08/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |